Dutch MEB defines QR code policy

3 November 2014

The Netherlands Medicines Evaluation Board (MEB) has defined policy regarding the use of QR codes on the outer packaging and/or in the package leaflet for medicinal products. The policy outlines the conditions that QR code (a type of two dimensional barcode) use must fulfil.

With this policy, the MEB addresses companies' demands for making product information available via QR codes. These QR codes can be read using mobile devices (smartphone, tablet). This policy was developed in cooperation with companies, holders and applicants of marketing authorizations. The same approach applies to technologies with the same purpose as the QR code.

Also applies to parallel-imported medicines

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK